Randomization and Masking
low disease activity
DISEASE, THIGH DISEASE, MAY, REMISSION, BLIND
From November 1, 2018, to May 28, 2019, eligible patients were randomly assigned at a 1:1 ratio into a SSDM group vs a conventional care control group. All patients were followed up with for 12 months. The randomization sequence was generated with an interactive web response system using a block design (block sizes of 4). The randomization was stratified based on the DAS28-CRP score at baseline (ie, remission [REM], DAS28-CRP ≤ 2.6 and low disease activity [LDA], 2.6-3.2; moderate disease activity [MDA], 3.2-5.1; or high disease activity [HDA], > 5.1), as assessed by the rheumatologists. The statisticians and the rheumatologists who assessed DAS28-CRP were blinded to group allocation. Investigators and participants were not blind to group assignment.